Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

被引:0
|
作者
Rothnie, Kieran J. [1 ,7 ]
Numbere, Beade [1 ]
Gelwicks, Steven [2 ]
Lu, Yifei [1 ,3 ]
Sharma, Raj [4 ]
Compton, Chris [4 ]
Ismaila, Afisi S. [2 ,5 ]
Quint, Jennifer K. [6 ]
机构
[1] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[2] GSK, Value Evidence & Outcomes, R&D Global Med, Collegeville, PA USA
[3] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA
[4] GSK, Global Med, London, England
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Imperial Coll London, Natl Heart & Lung Inst, London, England
[7] GSK, Value Evidence & Outcomes, R&D Global Med, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England
关键词
COPD; CPRD; exacerbation; GOLD A/B; risk factor; UK; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE; PREDICTION; OUTCOMES;
D O I
10.2147/COPD.S413947
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged >= 35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.
引用
收藏
页码:2673 / 2685
页数:13
相关论文
共 50 条
  • [11] Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice
    Chalmers, James D.
    Tebboth, Abigail
    Gayle, Alicia
    Ternouth, Andrew
    Ramscar, Nick
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2017, 27
  • [12] Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice
    James D. Chalmers
    Abigail Tebboth
    Alicia Gayle
    Andrew Ternouth
    Nick Ramscar
    npj Primary Care Respiratory Medicine, 27
  • [13] Risk Factors Associated with the Incidence of Vaginitis and Balinitis among Patients with Type 2 Diabetes in a Community Practice Setting in the UK
    Gomez-Caminero, Andres
    Hirji, Ishan
    Andersson, Susan
    Hammar, Niklas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S287 - S287
  • [14] Factors Associated with Time to Triple Therapy in Newly Diagnosed COPD Patients in the UK General Practice Research Database
    Wurst, Keele E.
    Bushnell, Greta
    Shukla, Amit
    Muellerova, Hana
    Davis, Kourtney J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 33 - 33
  • [15] Risk Factors Associated with the Incidence of Urinary Tract Infections among Patients with Type 2 Diabetes in a Community Practice Setting in the UK
    Gomez-Caminero, Andres
    Hirji, Ishan
    Andersson, Susan
    Hammar, Niklas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S287 - S288
  • [16] Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients:: A multiple logistic regression analysis
    Miravitlles, M
    Guerrero, T
    Mayordomo, C
    Sánchez-Agudo, L
    Nicolau, F
    Segú, JL
    RESPIRATION, 2000, 67 (05) : 495 - 501
  • [17] Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study
    Muellerova, Hana
    Finch, Donna K.
    Agusti, Alvar
    Alacqua, Marianna
    Anderson, Gary P.
    Beasley, Richard
    Belton, Laura
    De Giorgio-Miller, Alex
    Fitzgerald, J. Mark
    Hughes, Rod
    Pavord, Ian D.
    Price, David
    Rapsomaniki, Eleni
    Sadatsafavi, Mohsen
    Vestbo, Jorgen
    Bel, Elisabeth H.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [18] Clinical characteristics and risk factors of virus or influenza infection among the hospitalized pneumonia in COPD patients
    Kim, YuJin
    Kyung, Sun Young
    Hwang, Hyun Joong
    Park, Jeong-Woong
    Kang, Shin Myung
    Jeong, Sung Hwan
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [19] Factors associated with uptake of seasonal and pandemic influenza vaccine among clinical risk groups in the UK: An analysis using the General Practice Research Database
    Sammon, Cormac J.
    McGrogan, Anita
    Snowball, Julia
    de Vries, Corinne S.
    VACCINE, 2012, 30 (14) : 2483 - 2489
  • [20] Prevalence, risk factors, and clinical characteristics of pulmonary embolism in patients with acute exacerbation of COPD in Plateau regions: a prospective cohort study
    Chenlu Yang
    Yajun Tuo
    Xuefeng Shi
    Jie Duo
    Xin Liu
    Fang Zhang
    Xiaokai Feng
    BMC Pulmonary Medicine, 24